Evidence map›Paper›PMID 41672595›Full record

ArticleJournal for immunotherapy of cancer2026

Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer.

Jiazhuo He, Lydia Kirsche, Zuzana Nascakova, Francesco Manfredi, Chiara F Magnani, Giovanni Papa, Flora Azizi, Peter Leary, Anne Müller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiazhuo He *Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
Lydia Kirsche *Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
Zuzana NascakovaInstitute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
Francesco ManfrediDepartment of Medical Oncology and Hematology, University of Zürich and University Hospital Zürich, Zurich, Switzerland.
Chiara F MagnaniDepartment of Medical Oncology and Hematology, University of Zürich and University Hospital Zürich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2474-2159
Giovanni PapaInstitute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
Flora AziziInstitute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
Peter LearyInstitute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland.
Anne MüllerInstitute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland mueller@imcr.uzh.ch.ORCID http://orcid.org/0000-0002-1368-8276

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundERBB2/HER2 is overexpressed or mutated in ~15% of gastric cancers due to amplification or mutation of the

methodsWe have developed genetically engineered ectopic and orthotopic syngeneic models of organoid-based gastric cancer that have allowed us to study the tumor microenvironment of ErbB2-overexpressing tumors, using spectral flow cytometry, single cell RNA sequencing, and TCR repertoire sequencing. Interventions such as anti-Erbb2 and anti-PD1 antibody treatments were used as well.

resultsWe find that ErbB2 drives the infiltration of CD4

conclusionsThe combined data indicate that ErbB2, perhaps by driving micronuclei formation, has immunogenic properties that manifest in the form of increased T-cell infiltration and expansion, which can be exploited therapeutically by combining PD1-directed checkpoint blockade with ErbB2-targeted therapy.

Indexed as

Erb-b2 Receptor Tyrosine KinasesImmune Checkpoint InhibitorsStomach NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorDisease Models, AnimalFemaleGenetic EngineeringHumansLymphocytes, Tumor-InfiltratingMiceOrganoidsProgrammed Cell Death 1 ReceptorTumor MicroenvironmentERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorGastric CancerT cell Receptor - TCRTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Identifiers

PMID41672595
PMCPMC12911747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.